… transforming the treatment landscape for lung cancer, offering new hope for patients … with both small cell lung cancer (SCLC) and non-SCLC (NSCLC … ; Jazz), topotecan (Hycamtin; Sandoz), and amrubicin (Calsed; Nippon Kayaku). The results …

… with relapsed small-cell lung cancer (SCLC) compared to … patients with small-cell lung cancer (SCLC) whose disease … topotecan, lurbinectedin, or amrubicin, while producing improvements in … in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …

… topotecan, lurbinectedin, or amrubicin. They were further stratified … in Relapsed Small Cell Lung Cancer (DeLLphi-304). National … in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301 … DLL3 in small cell lung cancer and other neuroendocrine carcinomas. …

… cytologically confirmed small cell lung cancer who experienced disease progression … topotecan (185 patients), or amrubicin (23 patients). Stratification factors … intended chemotherapy (topotecan/amrubicin versus lurbinectedin). Overall survival served …

… immunotherapies for our patients with lung cancer.” Rudin is deputy director of … = 47), topotecan (n = 185), or amrubicin (n = 23). Stratification factors included … ), and intended chemotherapy (topotecan/amrubicin vs lurbinectedin). OS served as …

… extensive-stage small cell lung cancer (ES-SCLC). “This … Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin … phase III trial of amrubicin versus topotecan as second … cell lung cancer progression after 2 lines of therapy. Lung Cancer. …

… patients with small cell lung cancer. Lung Cancer . 2020;147:237-243 … Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, … III trial of amrubicin versus topotecan as second … cell lung cancer progression after 2 lines of therapy. Lung Cancer . …

… living with small cell lung cancer face poor outcomes with … I-DXd compared to amrubicin, lurbinectedin or topotecan … With Relapsed Small Cell Lung Cancer (IDeate-Lung02) ClinicalTrials. … ;NCT06203210 3. Small Cell Lung Cancer Treatment (PDQ)–Patient Version …

… -DXd against second-line options amrubicin, lurbinectedin, or topotecan. The dual … type of lung cancer, accounting for about 15% of all lung cancers, with overexpression … EGFR-mutated non-small-cell lung cancer (NSCLC). The regulator gave manufacturing …

… with relapsed small cell lung cancer (SCLC) versus treatment … 2023 World Conference on Lung Cancer hosted by the … s choice of chemotherapy (amrubicin, lurbinectedin or topotecan) in … lung cancer cases were diagnosed globally in 2022. Small cell lung cancer …